Tailored hydration using ReDS lung‑water monitoring to prevent kidney injury during coronary angiography and intervention
Clinical Study on Tailored Hydration by Remote Dielectric Sensing System to Prevent Acute Renal Injury in Elderly Patients With Renal Insufficiency After Coronary Angiography
This trial tests whether using a ReDS lung‑water monitor to guide IV fluids can lower the risk of contrast‑induced acute kidney injury in people aged 60 and older with reduced kidney function having coronary angiography or PCI.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 320 (estimated) |
| Ages | 60 Years and up |
| Sex | All |
| Sponsor | Chinese PLA General Hospital Academic / other |
| Locations | 1 site (Beijing, Beijing Municipality) |
| Trial ID | NCT07394959 on ClinicalTrials.gov |
What this trial studies
Elderly patients with coronary disease often have chronic kidney disease and are at risk for contrast‑induced acute kidney injury (CI‑AKI) after percutaneous coronary intervention. This randomized interventional study compares tailored hydration guided by the Remote Dielectric Sensing (ReDS) lung‑water index versus standard hydration in patients scheduled for coronary intervention. The ReDS device is used to dynamically monitor lung water and adjust infusion rates to avoid fluid overload and acute pulmonary edema while providing necessary hydration. Outcomes include perioperative CI‑AKI, acute pulmonary edema, and longer‑term major cardiovascular events and need for hemodialysis.
Who should consider this trial
Good fit: Ideal candidates are patients aged 60 or older with unstable angina scheduled for coronary intervention who have chronic kidney disease (eGFR between 30 and 90 mL/min) and can provide informed consent.
Not a fit: Patients with severe renal failure (eGFR <30 mL/min), acute decompensated heart failure, respiratory failure, recent contrast exposure, or known contrast allergy are unlikely to benefit or are excluded.
Why it matters
Potential benefit: If successful, this approach could reduce contrast‑related kidney injury while lowering the risk of fluid‑overload complications like pulmonary edema.
How similar studies have performed: Personalized hydration strategies and various lung‑fluid monitoring approaches have shown promise in reducing CI‑AKI in some reports, but use of ReDS guidance for this indication is relatively novel and not yet widely validated.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age ≥ 60 years; * Patients with unstable angina pectoris are scheduled for percutaneous coronary intervention； * Patients with chronic renal disease (estimated glomerular filtration rate \< 90 ml/min); * Sign the informed consent form. Exclusion Criteria: * 1\. Acute decompensated severe heart failure or cardiogenic shock; * 2\. Malignant tumors, severe renal failure (estimated glomerular filtration rate \< 30 ml/min); * 3\. Respiratory failure; * 4\. Used contrast media within one week; * 5\. Have allergic to contrast medium
Where this trial is running
Beijing, Beijing Municipality
- Chinese PLA general hospital — Beijing, Beijing Municipality, China (Recruiting)
Study contacts
- Study coordinator: Geng Qian, MD
- Email: qiangeng9396@263.net
- Phone: 086-010-55499209
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.